GLP-1 mimetics and diabetic ketoacidosis: possible interactions and clinical consequences
The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Abstract
Diabetic ketoacidosis is a serious diabetes-related consequence that occurs in type 1 diabetes and less commonly in type 2 diabetes and is a major cause of death. It results from the metabolic consequences due to a lack of insulin secretion or impaired insulin activity in diabetes leading to dysregulated pathophysiologic pathways resulting in excessive ketone body formation. While ketone bodies are physiologic molecules, their high levels reduce the physiological pH of the blood and induce ketoacidosis, leading to increasing metabolic dysfunction. Glucagon-like peptide-1 (GLP-1) mimetics are a class of recently developed diabetes therapy that do not lead to hypoglycemic, but some reports have suggested a relationship between GLP-1 mimetics and ketogenesis. To clarify the possible interactions between GLP-1 mimetics and ketogenesis in diabetes, this review was undertaken to collate and interpret the literature.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216 · cited 1×
“The incidence of diabetes is increasing, mainly caused by the worldwide growth in obesity incidence (Forouhi and Wareham 2010; Shaw et al. 2010).”
DrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861
2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s002 · Cited by 2,433 · cited 1×
“…diabetes in adults (LADA), maturity-onset diabetes of the young (MODY), and secondary diabetes resulting from conditions such as pancreatitis or certain medications, such as corticosteroids, which together form the fourth category of DM (Roglic 2016; ElSayed et al. 2023; Kaul et al. 2013).”
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“It is produced by the pro-glucagon gene in the L-cells of the intestine, specifically in the epithelial layer of the ileum and colon (Bryant et al. 1983) and is released on ingestion of a meal (Müller et al. 2019).”
Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics
Puchalska, P., & Crawford, P. A. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.022 · Cited by 1,610 · cited 1×
“Hepatocytes transform free fatty acids (FFAs) into small, soluble metabolic molecules known as KBs (Ghimire et al. 2023) such as acetone, acetoacetate, and β-hydroxybutyrate (Puchalska and Crawford 2021, 2017).”
Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management
Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., et al. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00006 · Cited by 1,500 · cited 1×
“Despite the existence of multiple pharmaceutical interventions for the management of diabetes, the occurrence of DKA remains a concern among individuals with diabetes particularly those treated with insulin (Chaudhury et al. 2017).”
WHO Global report on diabetes: A summary
Roglic, G. (2016) · International Journal of Noncommunicable Diseases · doi:10.4103/2468-8827.184853 · Cited by 998 · cited 3×
“Suboptimal diabetes control gives rise to diabetes-related complications in several organ systems (Roglic 2016; Balaji et al. 2019), with a diminished quality of life, an increased mortality that pose a significant health economic burden (Forouhi and Wareham 2010).”
Ketone bodies as signaling metabolites
Newman, J. C., & Verdin, E. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.09.002 · Cited by 966 · cited 2×
“…and synthesizing specific biomolecules such as sterols, glycer-ophospholipids, and sphingolipids, and also playing a crucial part in the process of histone acetylation and the regulation of gene expression within cells (Puchalska and Crawford 2021; Newman and Verdin 2014; Yaribeygi et al. 2022b).”
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950 · cited 1×
“Incretins are a group of peptides that are released by the gastrointestinal tract after food consumption that include GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) (Nauck and Meier 2018; Yar-ibeygi et al. 2020a).”
Glucagon and regulation of glucose metabolism
Jiang, G., & Zhang, B. B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00492.2002 · Cited by 905 · cited 1×
“Glucagon is a catabolic hormone that is closely involved in glucose homeostasis and functions in an opposite manner to that of insulin, which is an anabolic hormone (Jiang and Zhang 2003).”
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
GIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746 · cited 1×
“Incretins are endogenous peptides with metabolic functions that are produced by the gastrointestinal tract (Seino et al. 2010) that include glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1(GLP-1) (Seino et al. 2010).”
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680 · cited 1×
“By this way, consequent insulin production is stimulated in a glucose-dependent manner (Doyle and Egan 2007).”
Rosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664 · cited 1×
“Consequently, this exchanger indirectly aids in regulating blood pH and preventing ketoacidosis (Yaribeygi et al. 2022a; Rosenstock and Ferrannini 2015; Martinez et al. 2018).”
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641 · cited 1×
“Also, they decrease obesity by stimulating lipolysis (Day et al. 2009) as suggested by Ruiz-Grande et al. in 1992 (Ruiz-Grande et al. 1992).”
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582 · cited 2×
“Additionally, it suggests that the responsiveness of β-cells to glucose can be raised to normal levels with the administration of a modest dose of the GLP-1 infusion (Kjems et al. 2003).”
α-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581 · cited 1×
“This is a significant aspect of GLP-1’s inhibitory effect on the α-cell (Gromada et al. 2007).”
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581 · cited 1×
“This suggests GLP-1 mimetics induce fewer DKA cases in comparison to SGLT2 inhibitors (Brown et al. 2021; Anson et al. 2023).”
Gutzwiller, J.-P., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 521
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498 · cited 1×
“Furthermore, there is data indicating that GLP-1 has an impact on the electrical activity and secretion of α-cells, even when there are no alterations in somatostatin or insulin levels (Sandoval and D'Alessio 2015).”
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487 · cited 12×
“When DPP-4 inhibitors are given, the concentration of endogenous GLP-1 increases by 2–3 times (Holst and Deacon 1998).”
InfluentialDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy
(2011) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott · Cited by 471
Effects of Ketone Bodies on Brain Metabolism and Function in Neurodegenerative Diseases
Jensen, N. J., Wodschow, H. Z., Nilsson, M., & Rungby, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228767 · Cited by 446 · cited 1×
“Moreover, they result in the generation of a significantly higher number of energy units compared to a glucose molecule (Jensen et al. 2020).”
Clinical Use of DPP-4 Inhibitors
Gallwitz, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00389 · Cited by 374 · cited 1×
“Anagliptin, gemigliptin, and teneligliptin are available in some Asian countries (Table 1) (Gallwitz 2019; Sesti et al. 2019).”
Gerich, J. E., Lorenzi, M., Bier, D. M., Schneider, V., Tsalikian, E., Karam, J. H., & Forsham, P. H. (1975) · New England Journal of Medicine · doi:10.1056/nejm197505082921901 · Cited by 354 · cited 1×
“…can only increase KB synthesis to a small extent when insulin signaling is fully eliminated, which is consistent with the previously documented direct effects of glucagon on hepatocytes (Capozzi et al. 2020; Malewiak et al. 1983; McGarry et al. 1975; Pégorier et al. 1989; Gerich et al. 1975).”
Introduction to Diabetes Mellitus
Kaul, K., Tarr, J. M., Ahmad, S. I., Kohner, E. M., & Chibber, R. (2013) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-5441-0_1 · Cited by 322
Diabetic ketoacidosis in children and adolescents with diabetes
Wolfsdorf, J., Craig, M. E., Daneman, D., Dunger, D., Edge, J., Lee, W., Rosenbloom, A., Sperling, M., & Hanas, R. (2009) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2009.00569.x · Cited by 313 · cited 12×
“The hormonal changes result in changes in the production of glucose via glycogenolysis and gluconeogenesis, an increase in the breakdown of fats, and the formation of KBs (Wolfsdorf et al. 2009).”
InfluentialMetabolic and Signaling Roles of Ketone Bodies in Health and Disease
Puchalska, P., & Crawford, P. A. (2021) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-111120-111518 · Cited by 282 · cited 2×
“…and synthesizing specific biomolecules such as sterols, glycer-ophospholipids, and sphingolipids, and also playing a crucial part in the process of histone acetylation and the regulation of gene expression within cells (Puchalska and Crawford 2021; Newman and Verdin 2014; Yaribeygi et al. 2022b).”
Crajoinas, R. O., Oricchio, F. T., Pessoa, T. D., Pacheco, B. P. M., Lessa, L. M. A., Malnic, G., & Girardi, A. C. C. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00729.2010 · Cited by 278
Alpha cell function in health and disease: influence of glucagon-like peptide-1
Dunning, B. E., Foley, J. E., & Ahrén, B. (2005) · Diabetologia · doi:10.1007/s00125-005-1878-0 · Cited by 271 · cited 1×
“The activation of the GLP-1 receptor suppresses the secretion of glucagon from isolated islets or pancreas perfused ex vivo (Dunning et al. 2005).”
Euglycemic Diabetic Ketoacidosis: A Review
Modi, A., Agrawal, A., & Morgan, F. (2017) · Current Diabetes Reviews · doi:10.2174/1573399812666160421121307 · Cited by 264 · cited 3×
“This leads to elevated blood glucose levels, increased urine production, and more stress hormone release, worsening DKA decreased blood glucose levels (below 200 mg/dl) compared to DKA, which can result in a delayed diagnosis (Modi et al. 2017; Yaribeygi et al. 2022b; Barski et al. 2019).”
InfluentialGier, B., Matveyenko, A. V., Kirakossian, D., Dawson, D., Dry, S. M., & Butler, P. C. (2012) · Diabetes · doi:10.2337/db11-1109 · Cited by 255 · cited 2×
“This leads to a persistent state of inflammation and harm to the beta cells which in turn impairs insulin secretion (Gier et al. 2012; Jeong et al. 2023; Sharko et al. 2021).”
Physiology and pathophysiology of glucagon
Unger, R. H., & Orci, L. (1976) · Physiological Reviews · doi:10.1152/physrev.1976.56.4.778 · Cited by 253 · cited 1×
“It significantly enhances the production of cAMP in liver cells, which is a signal associated with the regulation of both lipid and glucose metabolism (Unger and Orci 1976).”
β Cell tone is defined by proglucagon peptides through cAMP signaling
Capozzi, M. E., Svendsen, B., Encisco, S. E., Lewandowski, S. L., Martin, M. D., Lin, H., Jaffe, J. L., Coch, R. W., Haldeman, J. M., MacDonald, P. E., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126742 · Cited by 250 · cited 1×
“Therefore, GLP-1 significantly raises β-cell activity and insulin release by activating the GLP-1 receptors (Capozzi et al. 2019a; Capozzi et al. 2019b; Gu et al. 2010).”
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
Chan, J. C. N., Scott, R., Arjona Ferreira, J. C., Sheng, D., Gonzalez, E., Davies, M. J., Stein, P. P., Kaufman, K. D., Amatruda, J. M., & Williams‐Herman, D. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00914.x · Cited by 238
McGarry, J., Wright, P. H., & Foster, D. W. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108038 · Cited by 227 · cited 1×
“…can only increase KB synthesis to a small extent when insulin signaling is fully eliminated, which is consistent with the previously documented direct effects of glucagon on hepatocytes (Capozzi et al. 2020; Malewiak et al. 1983; McGarry et al. 1975; Pégorier et al. 1989; Gerich et al. 1975).”
Qiu, H., Novikov, A., & Vallon, V. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2886 · Cited by 226 · cited 1×
“Insulin decreases the levels of KBs by limiting the production of ketones in the liver and promoting the break-down of KBs in peripheral tissues (Qiu et al. 2017).”
Ahrén, B. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.07.005 · Cited by 204 · cited 1×
“GLP-1 is degraded by dipeptidyl peptidase-4 (DPP-4) enzyme through its proteolytic activity (Al-Badri et al. 2018); therefore, DPP-4 inhibitors result in in more prolonged physiological levels of GLP-1 (Ahrén 2007).”
McDonough, A. A. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00002.2010 · Cited by 196 · cited 1×
“5) (Yaribeygi et al. 2022a; Li et al. 2013; McDonough 2010).”
Euglycemic diabetic ketoacidosis
Barski, L., Eshkoli, T., Brandstaetter, E., & Jotkowitz, A. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.03.014 · Cited by 176 · cited 3×
“One of the serious and well-documented complications of diabetes mellitus is diabetic ketoacidosis (DKA) which is an acute hyperglycemic emergency that has an associated mortality (Barski et al. 2019).”
Glucocorticoid-Induced Fatty Liver Disease
Rahimi, L., Rajpal, A., & Ismail‐Beigi, F. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s247379 · Cited by 176 · cited 13×
“The hormonal changes result in changes in the production of glucose via glycogenolysis and gluconeogenesis, an increase in the breakdown of fats, and the formation of KBs (Wolfsdorf et al. 2009).”
InfluentialGlucagon lowers glycemia when β cells are active
Capozzi, M. E., Wait, J. B., Koech, J., Gordon, A. N., Coch, R. W., Svendsen, B., Finan, B., D’Alessio, D. A., & Campbell, J. E. (2019) · JCI Insight · doi:10.1172/jci.insight.129954 · Cited by 165 · cited 1×
“Therefore, GLP-1 significantly raises β-cell activity and insulin release by activating the GLP-1 receptors (Capozzi et al. 2019a; Capozzi et al. 2019b; Gu et al. 2010).”
Forouhi, N. G., & Wareham, N. J. (2010) · Medicine · doi:10.1016/j.mpmed.2010.08.007 · Cited by 165
Kitabchi, A. E., & Wall, B. M. (1995) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30082-7 · Cited by 157
Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes
Arslanian, S. A., Hannon, T., Zeitler, P., Chao, L. C., Boucher-Berry, C., Barrientos-Pérez, M., Bismuth, E., Dib, S., Cho, J. I., & Cox, D. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204601 · Cited by 150
Adverse drug reactions of GLP-1 agonists: A systematic review of case reports
Shetty, R., Basheer, F. T., Poojari, P. G., Thunga, G., Chandran, V. P., & Acharya, L. D. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102427 · Cited by 145 · cited 1×
“Its primary function is to stimulate the pancreas to secrete insulin in a glucose-dependent manner while reducing postprandial glucagon hormone release limiting food consumption (Yaribeygi et al. 2019a; Shetty et al. 2022).”
Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys
Yaribeygi, H., Katsiki, N., Butler, A. E., & Sahebkar, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.08.005 · Cited by 140 · cited 3×
“Its primary function is to stimulate the pancreas to secrete insulin in a glucose-dependent manner while reducing postprandial glucagon hormone release limiting food consumption (Yaribeygi et al. 2019a; Shetty et al. 2022).”
Self-citationGirardi, A. C. C., DeGray, B., Nagy, T., Biemesderfer, D., & Aronson, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106897200 · Cited by 129 · cited 2×
“This reabsorption process occurs through this exchanger (Avogaro et al. 2014; Girardi et al. 2001), and the resultant H + ions are the result of the carbonic anhy-drase enzyme and bicarbonate creation.”
Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus
Keating, G. M. (2014) · Drugs · doi:10.1007/s40265-014-0199-3 · Cited by 126
Pacheco, B. P., Crajoinas, R. O., Couto, G. K., Davel, A. P. C., Lessa, L. M., Rossoni, L. V., & Girardi, A. C. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e328341939d · Cited by 125 · cited 1×
“It has been shown that sitagliptin effectively lowered blood pressure levels associated with renal sodium/hydrogen co-transport in spontaneously hypertensive rats by natriuresis (Pacheco et al. 2011; Avogaro et al. 2014; Girardi et al. 2001).”
Calimag, A. P. P., Chlebek, S., Lerma, E. V., & Chaiban, J. T. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101418 · Cited by 122 · cited 1×
“…(DKA) is a severe hyperglycemia emergency that is primarily defined by the triad of high blood sugar levels (blood sugar > 250 mg/dl), ketosis, and metabolic acidosis with an increased anion gap (arterial pH < 7.3 and serum bicarbonate < 18 mmEq/L) (Calimag et al. 2023; Modi et al. 2017).”
InfluentialDozio, E., Vianello, E., Malavazos, A. E., Tacchini, L., Schmitz, G., Iacobellis, G., & Corsi Romanelli, M. M. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.04.039 · Cited by 118 · cited 2×
“GLP-1 also interacts with genes associated with fatty acid beta-oxidation (Dozio et al. 2019). incretin-based medicines have the potential to regulate lipolysis (Zilleßen et al. 2016).”
Åhrén, B. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.01.010 · Cited by 112 · cited 2×
“The phenomenon can be linked to an increase in insulin secretion caused by the gut incretin hormones secreted in response to oral glucose (Ahrén 2011).”
The physiological role of glucagon-like peptide-1 in the regulation of renal function
Farah, L. X. S., Valentini, V., Pessoa, T. D., Malnic, G., McDonough, A. A., & Girardi, A. C. C. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00394.2015 · Cited by 111 · cited 1×
“These findings add to the growing body of evidence that GLP-1 is a physiologically important natriuretic factor that contributes to sodium balance in part through tonic modulation of NHE3 activity in the proximal tubule (Farah et al. 2016).”
Ranjbar, G., Mikhailidis, D. P., & Sahebkar, A. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154001 · Cited by 107
Self-citationVildagliptin: A Review of its Use in Type 2 Diabetes Mellitus
Keating, G. M. (2010) · Drugs · doi:10.2165/11206370-000000000-00000 · Cited by 107
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
Anson, M., Zhao, S. S., Austin, P., Ibarburu, G. H., Malik, R. A., & Alam, U. (2023) · Diabetologia · doi:10.1007/s00125-023-05975-8 · Cited by 103 · cited 1×
“This suggests GLP-1 mimetics induce fewer DKA cases in comparison to SGLT2 inhibitors (Brown et al. 2021; Anson et al. 2023).”
Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity
Yaribeygi, H., Sathyapalan, T., & Sahebkar, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116776 · Cited by 102 · cited 3×
“Its primary function is to stimulate the pancreas to secrete insulin in a glucose-dependent manner while reducing postprandial glucagon hormone release limiting food consumption (Yaribeygi et al. 2019a; Shetty et al. 2022).”
Self-citationYaribeygi, H., Rashidy-Pour, A., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118645 · Cited by 96 · cited 3×
“In 2001, Yaney et al. showed that GLP-1 stimulates the breakdown of fats and the release of free fatty acids in clonal pancreatic beta cells through a mechanism that depends on cAMP (Yaribeygi et al. 2021).”
Self-citationTen years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus
Sesti, G., Avogaro, A., Belcastro, S., Bonora, B. M., Croci, M., Daniele, G., Dauriz, M., Dotta, F., Formichi, C., Frontoni, S., et al. (2019) · Acta Diabetologica · doi:10.1007/s00592-018-1271-3 · Cited by 94 · cited 1×
“Anagliptin, gemigliptin, and teneligliptin are available in some Asian countries (Table 1) (Gallwitz 2019; Sesti et al. 2019).”
The Role of GLP-1 in the Life and Death of Pancreatic Beta Cells
Perfetti, R., & Hui, H. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826167 · Cited by 90 · cited 1×
“GLP-1 may also prevents the apoptosis of beta cells shown in animal studies (Perfetti and Hui 2004).”
Lipolytic action of glucagon-like peptides in isolated rat adipocytes
Ruiz-Grande, C., Alarcón, C., Mérida, E., & Valverde, I. (1992) · Peptides · doi:10.1016/0196-9781(92)90134-o · Cited by 89 · cited 1×
“Also, they decrease obesity by stimulating lipolysis (Day et al. 2009) as suggested by Ruiz-Grande et al. in 1992 (Ruiz-Grande et al. 1992).”
Edwards, K., Li, X.-L., & Lingvay, I. (2022) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/clinem/dgac618 · Cited by 85
Lixisenatide for type 2 diabetes mellitus
Christensen, M., Knop, F. K., Vilsbøll, T., & Holst, J. J. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.562191 · Cited by 84
Dhillon, S., & Weber, J. (2009) · Drugs · doi:10.2165/11201170-000000000-00000 · Cited by 82
Metabolic role of dipeptidyl peptidase 4 (DPP4) in primary human (pre)adipocytes
Zilleßen, P., Celner, J., Kretschmann, A., Pfeifer, A., Racké, K., & Mayer, P. E. (2016) · Scientific Reports · doi:10.1038/srep23074 · Cited by 79 · cited 1×
“GLP-1 also interacts with genes associated with fatty acid beta-oxidation (Dozio et al. 2019). incretin-based medicines have the potential to regulate lipolysis (Zilleßen et al. 2016).”
Li, H. C., Du, Z., Barone, S., Rubera, I., McDonough, A. A., Tauc, M., Zahedi, K. A., Wang, T., & Soleimani, M. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1015-3 · Cited by 74 · cited 1×
“5) (Yaribeygi et al. 2022a; Li et al. 2013; McDonough 2010).”
Henness, S., & Keam, S. J. (2006) · Drugs · doi:10.2165/00003495-200666150-00007 · Cited by 72
Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes
Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117152 · Cited by 71 · cited 1×
“Besides, these drugs have been reported to exert diverse pharmacological effects that may extend beyond T2DM management (Yaribeygi et al. 2021, 2020, 2019b, 2020b; Rezaei et al. 2021; Ashrafizadeh et al. 2019; Ran-jbar et al. 2019).”
Self-citationLong-acting preparations of exenatide
Yuan, W., Cai, Y., Wei, L. L., Ma, L., Huang, X., Tao, A., & Liu, Z. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s46970 · Cited by 69
The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition
Capozzi, M. E., Coch, R. W., Koech, J., Astapova, I. I., Wait, J. B., Encisco, S. E., Douros, J. D., EL, K. M., Finan, B., Sloop, K. W., et al. (2020) · Diabetes · doi:10.2337/db19-1216 · Cited by 65 · cited 7×
“It has been suggested that the ratio of insulin to glucagon in the plasma determines the rates at which ketogenesis occurs (Capozzi et al. 2020).”
InfluentialRezaei, S., Tabrizi, R., Nowrouzi-Sohrabi, P., Jalali, M., Atkin, S. L., Al-Rasadi, K., Jamialahmadi, T., & Sahebkar, A. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/8936865 · Cited by 65 · cited 1×
“Besides, these drugs have been reported to exert diverse pharmacological effects that may extend beyond T2DM management (Yaribeygi et al. 2021, 2020, 2019b, 2020b; Rezaei et al. 2021; Ashrafizadeh et al. 2019; Ran-jbar et al. 2019).”
Self-citationAlogliptin: a new addition to the class of DPP-4 inhibitors
Rendell, M. (2009) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s4312 · Cited by 64
Guidelines for management of diabetic ketoacidosis: time to revise?
Dhatariya, K., & Umpierrez, G. E. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30093-1 · Cited by 64 · cited 2×
“Consequently, inadequate amounts of insulin lead to elevated blood glucose levels that subsequently induce excessive urine production and the release of additional stress hormones by the body (Lowie and Bond 2023; Wolfsdorf et al. 2009; Dhatariya and Umpierrez 2017).”
Barnett, A. H. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01523.x · Cited by 60 · cited 11×
“There are four main types of diabetes including type 1 (T1DM), which is caused by insufficient insulin production from the pancreas; type 2 (T2DM), which is caused by insulin resistance in adipocytes and skeletal muscle cells and a gradual decline in insulin production; gestational diabetes, which develops during preg…”
InfluentialScott, L. J. (2011) · Drugs · doi:10.2165/11207400-000000000-00000 · Cited by 60
Pégorier, J. P., Garcia-Garcia, M. V., Prip-Buus, C., Duée, P. H., Kohl, C., & Girard, J. (1989) · Biochemical Journal · doi:10.1042/bj2640093 · Cited by 59 · cited 1×
“…can only increase KB synthesis to a small extent when insulin signaling is fully eliminated, which is consistent with the previously documented direct effects of glucagon on hepatocytes (Capozzi et al. 2020; Malewiak et al. 1983; McGarry et al. 1975; Pégorier et al. 1989; Gerich et al. 1975).”
Starvation-induced True Diabetic Euglycemic Ketoacidosis in Severe Depression
Joseph, F., Anderson, L., Goenka, N., & Vora, J. (2008) · Journal of general internal medicine · doi:10.1007/s11606-008-0829-0 · Cited by 59 · cited 2×
“However, they are still susceptible to KB production and can develop DKA even with minimal increases in blood glucose levels or even when blood glucose levels are relatively normal (Joseph et al. 2009).”
Measurement of gut hormonal peptides in biopsies from human stomach and proximal small intestine.
Bryant, M. G., Bloom, S. R., Polak, J. M., Hobbs, S., Domschke, W., Domschke, S., Mitznegg, P., Ruppin, H., & Demling, L. (1983) · Gut · doi:10.1136/gut.24.2.114 · Cited by 57 · cited 1×
“It is produced by the pro-glucagon gene in the L-cells of the intestine, specifically in the epithelial layer of the ileum and colon (Bryant et al. 1983) and is released on ingestion of a meal (Müller et al. 2019).”
Khound, R., Taher, J., Baker, C., Adeli, K., & Su, Q. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310251 · Cited by 57 · cited 1×
“GLP-1 signaling triggers an inherent signal that promotes the breakdown of fatty acids (Khound et al. 2017b).”
Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990474 · Cited by 54 · cited 2×
“This reabsorption process occurs through this exchanger (Avogaro et al. 2014; Girardi et al. 2001), and the resultant H + ions are the result of the carbonic anhy-drase enzyme and bicarbonate creation.”
Gu, W., Winters, K. A., Motani, A. S., Komorowski, R., Zhang, Y., Liu, Q., Wu, X., Rulifson, I. C., Sivits, G., Graham, M., et al. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00102.2010 · Cited by 54 · cited 1×
“Therefore, GLP-1 significantly raises β-cell activity and insulin release by activating the GLP-1 receptors (Capozzi et al. 2019a; Capozzi et al. 2019b; Gu et al. 2010).”
MARTINEZ, R. A., Jobori, H. A., Ali, A. M., Adams, J. M., Abdul-Ghani, M. A., Triplitt, C. L., DeFronzo, R. A., & Cersósimo, E. (2018) · Diabetes · doi:10.2337/db17-1278 · Cited by 54 · cited 1×
“Consequently, this exchanger indirectly aids in regulating blood pH and preventing ketoacidosis (Yaribeygi et al. 2022a; Rosenstock and Ferrannini 2015; Martinez et al. 2018).”
Bray, G. M. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050459 · Cited by 52
Effects of newly introduced antidiabetic drugs on autophagy
Ashrafizadeh, M., Yaribeygi, H., Atkin, S. L., & Sahebkar, A. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.06.028 · Cited by 51 · cited 1×
“Besides, these drugs have been reported to exert diverse pharmacological effects that may extend beyond T2DM management (Yaribeygi et al. 2021, 2020, 2019b, 2020b; Rezaei et al. 2021; Ashrafizadeh et al. 2019; Ran-jbar et al. 2019).”
Self-citationLiraglutide: clinical pharmacology and considerations for therapy
Sisson, E. M. (2011) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.9.896 · Cited by 49
Alourfi, Z., & Homsi, H. (2015) · Avicenna Journal of Medicine · doi:10.4103/2231-0770.148503 · Cited by 48 · cited 1×
“Previous studies indicate that by investigating the factors that effect on DKA, it is possible to significantly reduce the occurrence of this medical emergency (Yaribeygi et al. 2022b; Alourfi and Homsi 2015).”
Nwia, S. M., Li, X. C., Leite, A. P. D. O., Hassan, R., & Zhuo, J. L. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.861659 · Cited by 46 · cited 1×
“Sodium-hydrogen exchanger 3 (NHE3) is an antiporter protein primarily located on the apical membrane of epithelial cells in the renal proximal tubule and thick ascending limb of Henle (Nwia et al. 2022).”
Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus
Tan, X., Pan, X., Wu, X., Zheng, S., Chen, Y., Liu, D., & Zhang, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.975880 · Cited by 44
Diabetic Retinopathy in Patients with Dyslipidemia: Development and Progression
Jeng, C., Hsieh, Y., Yang, C., Yang, C., Lin, C., & Wang, I. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.05.010 · Cited by 43 · cited 1×
“It was described that GLP-1 induces lipolysis in cultured rat adipocytes by activating distinct receptors from those used by the glucagon hormone (Jeng et al. 2018).”
Pinelli, N. R., Berlie, H. D., & Hurren (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s27528 · Cited by 41 · cited 1×
“However, there is some controversy with some reports suggesting ketogenic effects of GLP-1 (Alduraibi et al. 2023), whilst others have suggested the converse (Berlie et al. 2012; Tan et al. 2023) (Tables 2 and 3).”
Pathophysiology of ketoacidosis in Type 2 diabetes mellitus
Linfoot, P., Bergstrom, C., & Ipp, E. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01660.x · Cited by 39 · cited 1×
“Acetone is produced through the process of spontaneous decarboxylation of acetoacetate (Ghimire et al. 2023; Linfoot et al. 2005; Dhillon and Gupta 2023; Trugo and Finglas 2003; Caballero et al. 2003).”
Tackling dipeptidyl peptidase IV in neurological disorders
Castorina, A., Al‐Badri, G., Leggio, G. M., Musumeci, G., Marzagalli, R., & Drago, F. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.224365 · Cited by 39
Yang, Z., Yu, M., Mei, M., Chen, C., Lv, Y., Xiang, L., & Li, R. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.10.003 · Cited by 37 · cited 4×
“%) were associated with lower rates of DKA (Yang et al. 2022).”
InfluentialScheen, A. J. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101275 · Cited by 36 · cited 1×
“Additionally, recent studies have indicated that these agents may be associated with an enhanced frequency of DKA (Scheen 2021; Yang et al. 2022).”
Novel developments in differentiating the role of renal and intestinal sodium hydrogen exchanger 3
Rieg, J. A. D., Chavez, S. D. L. M., & Rieg, T. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00372.2016 · Cited by 35 · cited 2×
“It is also present on the apical membrane of enterocytes in the large and small intestines, as well as on the basolateral side of duodenal and pancreatic cells (Dominguez Rieg et al. 2016).”
A Review on the Effects of New Anti-Diabetic Drugs on Platelet Function
Yaribeygi, H., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666191014110414 · Cited by 34 · cited 1×
“Besides, these drugs have been reported to exert diverse pharmacological effects that may extend beyond T2DM management (Yaribeygi et al. 2021, 2020, 2019b, 2020b; Rezaei et al. 2021; Ashrafizadeh et al. 2019; Ran-jbar et al. 2019).”
Self-citationTanaka, T., Nangaku, M., & Nishiyama, A. (2011) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328349af9d · Cited by 31 · cited 1×
“The administration of DPP4 inhibitors may disrupt the process of sodium reabsorption, leading to a considerable rise in natriuresis and a reduction in blood pressure levels (Tanaka et al. 2011) and also storing H + in body.”
Fala, L. (2015) · PubMed · Cited by 31
Kamata, Y., Takano, K., Kishihara, E., Watanabe, M., Ichikawa, R., & Shichiri, M. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.06.023 · Cited by 31 · cited 11×
“There are four main types of diabetes including type 1 (T1DM), which is caused by insufficient insulin production from the pancreas; type 2 (T2DM), which is caused by insulin resistance in adipocytes and skeletal muscle cells and a gradual decline in insulin production; gestational diabetes, which develops during preg…”
InfluentialNEW THERAPEUTIC APPROACHES IN TYPE 2 DIABETES
Scheen, A. J. (2008) · Acta Clinica Belgica · doi:10.1179/acb.2008.083 · Cited by 28 · cited 11×
“There are four main types of diabetes including type 1 (T1DM), which is caused by insufficient insulin production from the pancreas; type 2 (T2DM), which is caused by insulin resistance in adipocytes and skeletal muscle cells and a gradual decline in insulin production; gestational diabetes, which develops during preg…”
InfluentialAntioxidative Potentials of Incretin‐Based Medications: A Review of Molecular Mechanisms
Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9959320 · Cited by 26 · cited 3×
“In 2001, Yaney et al. showed that GLP-1 stimulates the breakdown of fats and the release of free fatty acids in clonal pancreatic beta cells through a mechanism that depends on cAMP (Yaribeygi et al. 2021).”
Self-citationLi, P., Liu, X., Cui, B., Liu, Y., Wang, C., & Zhao, B. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.813083 · Cited by 23 · cited 1×
“During clinical practice, it is possible for certain patients with acute pancreatitis and diabetes mellitus to develop DKA (Diabetic and alcoholic 2023; Ma et al. 2022).”
Malewiak, M. I., Griglio, S., Kalopissis, A. D., & Lièpvre, X. L. (1983) · Metabolism · doi:10.1016/0026-0495(83)90121-x · Cited by 22 · cited 1×
“…can only increase KB synthesis to a small extent when insulin signaling is fully eliminated, which is consistent with the previously documented direct effects of glucagon on hepatocytes (Capozzi et al. 2020; Malewiak et al. 1983; McGarry et al. 1975; Pégorier et al. 1989; Gerich et al. 1975).”
COFFEE | Analysis of Coffee Products
Trugo, L. C. (2003) · Elsevier eBooks · doi:10.1016/b0-12-227055-x/00271-6 · Cited by 22
Euglycemic diabetic ketoacidosis after the initiation of dulaglutide in patient with type 2 diabetes
Alduraibi, R. K., Alrebdi, Y. M., & Altowayan, Y. F. (2023) · Medicine · doi:10.1097/md.0000000000034027 · Cited by 21
Lowie, B., & Bond, M. C. (2023) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2023.06.002 · Cited by 11 · cited 2×
“Although this condition is more common in T1DM, it can also occur in T2DM (Kamata et al. 2017) especially following surgery, trauma or infections (Lowie and Bond 2023).”
InfluentialNew insights into cellular links between sodium–glucose cotransporter‐2 inhibitors and ketogenesis
Yaribeygi, H., Maleki, M., Butler, A. E., Jamialahmadi, T., & Sahebkar, A. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30327 · Cited by 9 · cited 9×
“This leads to elevated blood glucose levels, increased urine production, and more stress hormone release, worsening DKA decreased blood glucose levels (below 200 mg/dl) compared to DKA, which can result in a delayed diagnosis (Modi et al. 2017; Yaribeygi et al. 2022b; Barski et al. 2019).”
InfluentialSelf-citationSynergistic inhibition of hepatic ketogenesis in the presence of insulin and a cAMP antagonist
Olivieri, M. C., & Botelho, L. H. P. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)90057-0 · Cited by 7 · cited 1×
“Furthermore, insulin can exert direct effects on hepatocytes by reducing intracellular cAMP levels, which is a signaling molecule associated with both lipid and glucose metabolism (Capozzi et al. 2020; Olivieri and Botelho 1989).”
Acute Pancreatitis Induced by Linagliptin: A Rare but Dangerous Side Effect
Sharko, A., Samuel, S., & Jain, N. (2021) · Cureus · doi:10.7759/cureus.14104 · Cited by 7 · cited 1×
“This leads to a persistent state of inflammation and harm to the beta cells which in turn impairs insulin secretion (Gier et al. 2012; Jeong et al. 2023; Sharko et al. 2021).”
Jeong, S., Vorachitti, M., & Fernando Jose Fuentes MD, F. (2023) · Cureus · doi:10.7759/cureus.39012 · Cited by 4 · cited 2×
“This leads to a persistent state of inflammation and harm to the beta cells which in turn impairs insulin secretion (Gier et al. 2012; Jeong et al. 2023; Sharko et al. 2021).”
Diabetic, Alcoholic, and Starvation Ketoacidosis
Reddi, A. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-25810-7_32 · Cited by 2
Research works printed but not linked: 3
- Balaji R, Duraisamy R, Kumar M (2019) Complications of diabetes mellitus: a review. Drug Invent Today 12(1)
- Caballero B, Trugo L, Finglas P (2003) Encyclopedia of food sciences and nutrition: Volumes 1–10: Elsevier Science BV
- Collins L, Costello R (2020) Glucagon-like peptide-1 receptor agonists. StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK551568/. Accessed 17 Aug 2024
Cited by
Ganamurali, N., & Sabarathinam, S. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.70001 · Cited by 8
“37 • Surrogate for future poly-agonist platforms : Retatru-tide is not just a single molecule but a proof-of-concept for multi-targeted pharmacotherapy.”
Xu, H., & Zhang, Y. L. (2026) · Medicine · doi:10.1097/md.0000000000046197 · Cited by 3
“[6] In our case, the patient’s preexisting T2DM with poor glycemic control (hemoglobin A1c 11.4”
InfluentialJayasingha, J. M. P. S., Madushan, M. A. H., Jayathilaka, N. S., & Sabarathinam, S. (2026) · Comprehensive physiology · doi:10.1002/cph4.70123
Metadata
- Authors
- Forouzanmehr, B., Hemmati, M. A., Atkin, S. L., Jamialahmadi, T., Yaribeygi, H., & Sahebkar, A.
- Affiliations
- Semnan University of Medical Sciences (IR)
- Royal College of Surgeons in Ireland - Bahrain (BH)
- Mashhad University of Medical Sciences (IR)
- Corresponding author
- Yaribeygi, Habib
- Sahebkar, Amirhossein
- ORCID
- Venue
- Naunyn-Schmiedeberg's Archives of Pharmacology
- Published
- 2024-08-22
- Volume
- 398
- Issue
- 1
- Pages
- 351-362
- ISSN
- 0028-1298 (ISSN-L)
- 1432-1912
- OpenAlex
- W4401793502
- Cited by
- 3
- References
- 113
- Citations by year
- 2026: 3
- FWCI
- 0.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Naunyn-Schmiedeberg s Archives of Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
- Keywords
- GLP-1 receptor agonists, diabetic ketoacidosis, ketogenesis, ketone bodies, type 1 diabetes, type 2 diabetes, insulin deficiency, drug interactions, metabolic dysfunction
- MeSH terms
- Animals, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Ketone Bodies, Diabetic Ketoacidosis, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.